Royalty Pharma plc (RPRX): A Technical Analysis
Royalty Pharma plc (NASDAQ: RPRX) has a higher price-to-earnings ratio of 18.07x compared to its average ratio. RPRX has 36-month beta value of 0.46. Analysts
Royalty Pharma plc (NASDAQ: RPRX) has a higher price-to-earnings ratio of 18.07x compared to its average ratio. RPRX has 36-month beta value of 0.46. Analysts
The stock price of Royalty Pharma plc (NASDAQ: RPRX) has plunged by -1.14 when compared to previous closing price of 27.75, but the company has
Royalty Pharma plc (NASDAQ: RPRX) has a higher price-to-earnings ratio of 18.53x compared to its average ratio. RPRX has 36-month beta value of 0.46. Analysts
Royalty Pharma plc (NASDAQ: RPRX) has a price-to-earnings ratio that is above its average at 18.21x. The stock has a 36-month beta value of 0.46.
© 2024, Powered by Smart TechOne
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.